Proteomic Profiles Differ Between Bone Invasive and Noninvasive Benign Meningiomas of Fibrous and Meningothelial Subtype
Overview
Authors
Affiliations
Meningiomas of WHO grade I can usually be cured by surgical resection. However, some tumors may, despite their benign appearance, display invasive growth behavior. These tumors constitute a difficult clinical problem to handle. By histology alone, bone invasive meningiomas may be indistinguishable from their noninvasive counterparts. In this study we have examined the protein spectra in a series of meningiomas in search of protein expression patterns that may distinguish between bone invasive and noninvasive meningiomas. Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI). Multivariate statistical methods were applied for data analyses. Comparing the protein spectra from invasive and noninvasive fibrous meningioma we found 22 peaks whose intensities were significantly different between the two groups (P < 0.001). Based on the expression pattern of these peaks we were able to perfectly separate the two entities (area under ROC curve = 1.0). In meningothelial meningioma the same comparison yielded six significantly differentially expressed peaks (P < 0.001), which to a large degree separated the invasive from noninvasive tissue (area under ROC curve = 0.873). By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I. A possibility for early identification of invasive grade I meningiomas may have a strong influence on the follow-up policy and the issue of early or late radiotherapy.
Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives.
Takase H, Yamamoto T Front Oncol. 2022; 12:895374.
PMID: 35847854 PMC: 9280135. DOI: 10.3389/fonc.2022.895374.
Multi-Omics Analysis in Initiation and Progression of Meningiomas: From Pathogenesis to Diagnosis.
Liu J, Xia C, Wang G Front Oncol. 2020; 10:1491.
PMID: 32983987 PMC: 7484374. DOI: 10.3389/fonc.2020.01491.
Proteomic analysis of meningiomas reveals clinically distinct molecular patterns.
Papaioannou M, Djuric U, Kao J, Karimi S, Zadeh G, Aldape K Neuro Oncol. 2019; 21(8):1028-1038.
PMID: 31077268 PMC: 6682208. DOI: 10.1093/neuonc/noz084.
Osbun J, Tatman P, Kaur S, Parada C, Busald T, Gonzalez-Cuyar L J Neurol Surg B Skull Base. 2017; 78(5):371-379.
PMID: 28875114 PMC: 5582960. DOI: 10.1055/s-0037-1601889.
Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.
Abbritti R, Polito F, Cucinotta M, Lo Giudice C, Caffo M, Tomasello C Cancer Genomics Proteomics. 2016; 13(5):369-79.
PMID: 27566655 PMC: 5070626.